A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Conditions

• Schizophrenia

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• ML-007C-MA — DRUG
  ML-007C-MA dosed as 210/3 mg BID

Study Details

ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

Key Dates

First listed

Mar 10, 2026

Start date

Mar 31, 2026

Status verified

Aug 2026

Primary completion

Feb 28, 2030

Completion

Feb 28, 2030

Study Design

Enrollment

500 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: ML-007C-MA

Primary Outcome Measure

To assess the safety and tolerability of long-term ML-007C-MA administration in adult participants with schizophrenia [ Time Frame: From initial dose through end of treatment (up to 52 weeks) ]

Central Contacts

• Clinical Trials Contact Center
  +1 650 839 4385
  [email protected]

Locations (41)

Find similar trials in Little Rock, AR

Related Studies

• Zyprexa® Relprevv™ Patient Care Program
  Enrolling By Invitation · Eli Lilly and Company · Blue Bell, Pennsylvania
• Database Registry for Neural Network Biomarkers in Psychosis
  Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas
• Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
  PHASE4 · Recruiting · Corporal Michael J. Crescenz VA Medical Center · Philadelphia, Pennsylvania
• Bromocriptine for Patients With Schizophrenia and Prediabetes
  PHASE4 · Not Yet Recruiting · VA Pittsburgh Healthcare System · Pittsburgh, Pennsylvania